PARIS – September 9, 2021 – The Phase 3 PEGASUS trial evaluating rilzabrutinib to treat pemphigus, a rare autoimmune skin condition, did not meet its primary or key secondary endpoints.

Please provide your email address to receive an email when new articles are posted on . A trial of adjuvant immunoadsorption for pemphigus diseases was ended early due to adverse events. The time to ...

Please provide your email address to receive an email when new articles are posted on . Patients with pemphigus treated with rituximab had a longer disease-free survival than those treated with ...

Paraneoplastic pemphigus is typically a side effect of a cancerous tumor and can cause mouth pain and oral sores. It can be aggressive and should be diagnosed and treated as soon as possible.

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Shares of argenx plummeted after lead asset Vyvgart (efgartigimod) failed to meet endpoints in a phase 3 trial for the treatment of pemphigus vulgaris and pemphigus foliaceus. The failure also has ...

Shares of argenx SE ARGX were down 25.1% on Dec 20 after the company announced top-line data from the phase III ADDRESS study, which evaluated efgartigimod subcutaneous (SC) (efgartigimod alfa and ...

Donna Culton, MD, University of North Carolina at Chapel Hill, outlines diagnosing autoimmune blistering diseases.